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Follicular DCs (FDCs) play a central yet in-
completely understood role in the adaptive im-
mune response (for review see Allen and Cyster, 
2008). As a major stromal cell constituent of 
both primary and secondary follicles, FDCs se-
crete chemokines such as CXCL13 to spatially 
organize the intrafollicular migration of B cells 
and follicular helper T cells. In addition, FDCs 
have the unique capacity to retain immune com-
plexes on their cell surface for week- to month-
long periods by virtue of their expression of 
FcRIIb Fc receptors and CR1 (CD35) and 
CR2  (CD21)  complement  receptors.  These 
immune complexes play a key role during the 
germinal center reaction, as they provide the 
antigenic substrate that drives antibody affinity 
maturation. Conversely, follicular B cells pro-
duce lymphotoxin 12 (LT12), which acts 
as a key FDC survival factor.
Contributions  of  FDCs  toward  T  cell   
immunity have been much less apparent. FDCs 
do not express MHCII molecules nor do they 
have the capacity to phagocytose and process 
exogenous antigens for MHCI-restricted pre-
sentation (Schnizlein et al., 1985; Gray et al., 
1991). Thus, it is unlikely that these cells present 
exogenous antigens to T cells. However, FDC-
bound antigen has been indirectly implicated 
in the extended phases of antigen presenta-
tion considered important for optimizing CD4   
T cell memory (van Essen et al., 2000). More-
over, it has recently been shown that FDC- 
retained  antigens,  in  the  form  of  antigen– 
antibody immune complexes, can be acquired 
by cognate B cells for processing and presentation 
to follicular helper T cells (Suzuki et al., 2009). 
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Follicular dendritic cells (DCs [FDCs]) are prominent stromal cell constituents of B cell 
follicles with the remarkable ability to retain complement-fixed antigens on their cell 
surface for extended periods of time. These retained immune complexes have long been 
known to provide the antigenic stimulus that drives antibody affinity maturation, but their 
role in cellular immunity has remained unclear. In this study, we show that FDC-retained 
antigens are continually sampled by lymph node–resident DCs for presentation to CD8  
T cells. This novel pathway of antigen acquisition was detectable when FDCs were loaded 
with purified antigens bound into classical antigen–antibody immune complexes, as well as 
after pregnancy, when they are loaded physiologically with antigens associated with the 
complement-fixed microparticles released from the placenta into maternal blood. In both 
cases, ensuing antigen presentation was profoundly tolerogenic, as it induced T cell deletion 
even under inflammatory conditions. These results significantly broaden the scope of FDC 
function and suggest new ways that the complement system and persistent antigen  
presentation might influence T cell activation and the maintenance of peripheral  
immune tolerance.
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mercial–Share Alike 3.0 Unported license, as described at http://creativecommons 
.org/licenses/by-nc-sa/3.0/).
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RESULTS
A prolonged period of postpartum antigen presentation 
correlates with the retention of shed placental antigen  
on LN FDCs
In accord with our previous results (Erlebacher et al., 2007), 
mating wild-type females to Act-mOVA transgenic males but not 
to control C57BL/6 (B6)–mated females led to the appearance 
by late gestation of OVA+ immunoreactive material on CD35+ 
FDC networks throughout all maternal secondary lymphoid 
organs, including the subcutaneous LNs and spleen (Fig. 1 A, 
top and middle). These OVA+ FDC networks were still visible 
3 wk after delivery (Fig. 1 A, bottom, arrows), and their exis-
tence surprisingly correlated to extended phases of OVA pre-
sentation to maternal T cells. Thus, naive CD8+ OT-I TCR 
transgenic T cells (Hogquist et al., 1994), which recognize the 
OVA257–264  peptide  presented  by  H-2Kb  (and  which  were 
crossed  onto  a  B6CBAF1  background  for  transfer  into  the 
B6CBAF1  females  used  in  these  experiments),  underwent   
antigen-driven proliferation when the cells were adoptively trans-
ferred into Act-mOVA–mated females 3–4 wk after delivery 
(Fig. 1 B; representative CFSE dilution plots are shown in   
Fig. 1 C). Robust OT-I proliferation (defined here as being the 
case when >25% of the cells divided more than once) and clear 
OVA+ FDC networks were frequently seen in the subcutaneous 
LNs of postpartum Act-mOVA–mated females, whereas persis-
tent OT-I proliferation and OVA+ FDC networks were much 
less apparent in the spleen. OVA+ FDC foci in the spleen, when 
detectable, were also much smaller than in the LNs.
The aforementioned data revealed an anatomical correla-
tion, and thus a potential link, between antigen retention on 
FDCs and persistent antigen presentation. This potential link 
was further strengthened by several additional considerations. 
First, we found that the intravenous injection of virgin or post-
partum B6-mated females with 100 µg soluble OVA only in-
duced an acute OT-I proliferative response that declined 
virtually to baseline levels by 7 d (Fig. S1 A). This result is con-
sistent with the estimated 2–14-d lifespan of lymphoid organ–
resident DCs (Kamath et al., 2002; Liu et al., 2007), which are 
the cells most often implicated in cross-presenting blood-borne 
antigens to naive CD8 T cells, and indicated that the postpar-
tum period was not associated with a general extension of APC 
lifespan. Second, serum OVA levels in late gestation Act-
mOVA–mated females were below our limit of detection by 
ELISA (10 ng/ml; unpublished data), and both pure OVA pro-
tein and soluble OVA-containing immune complexes are 
known to be rapidly cleared from the blood (t1/2 < 1 h) when 
injected intravenously at doses below 1 mg/mouse (Kim and 
Halsey, 1982; Carter et al., 1984). Third, persistent OVA presen-
tation could not be explained by the protracted release of   
residual OVA from the postpartum uterus, as Act-mOVA–mated 
females subjected to hysterectomies within 1 wk of delivery still 
showed robust OT-I proliferation in the subcutaneous LN and 
OVA immunoreactivity on LN FDCs when assessed 3 wk later 
(Fig. S1, B and C). Indeed, the observation of persistent OVA 
presentation in the LN but not the spleen was highly inconsis-
tent with OVA being continuously released into the blood 
These results extend older experiments demonstrating that 
the 0.3-µm-diameter immune complex–bearing bodies 
known as iccosomes can be acquired from the FDC cell 
surface by both germinal center B cells and tingible body mac-
rophages (Szakal et al., 1988). However, the possibility that 
DCs might also acquire FDC-bound immune complexes   
has not been directly addressed. Such an antigen transfer 
pathway would give FDC-bound antigens general access to 
both MHCI and MHCII presentation pathways and to a cell 
type with a central role in regulating both CD8 and CD4 T 
cell responses.
In the course of our previous work on the pathways that 
mediate the presentation of fetal/placental antigens during 
pregnancy, we noticed that the transgenic expression of a 
transmembrane form of the model antigen OVA by cells of 
the mouse conceptus not only induced the systemic prolif-
eration of antigen-specific maternal T cells but also led to 
the  accumulation  of  OVA+  immunoreactive  material  on 
FDCs throughout all maternal secondary lymphoid organs 
(Erlebacher et al., 2007). These experiments involved mat-
ing  wild-type  females  to  males  bearing  the Act-mOVA 
transgene, which directs relatively ubiquitous OVA expres-
sion from the -actin promoter (Ehst et al., 2003). Most 
likely, OVA had access to all maternal secondary lymphoid 
organs because the cell types expressing the transgene in-
cluded  labyrinthine  trophoblasts,  which  during  develop-
ment  establish  a  massive  degree  of  surface  contact  with 
maternal blood, as well as endovascular placental tropho-
blasts directly at the maternal/fetal interface, which showed 
particularly high transgene expression levels (Erlebacher   
et al., 2007). Moreover, it was likely that OVA was being 
shed into maternal blood through a process analogous to the 
hematogenous release of subcellular membranous material 
from the syncytiotrophoblast layer of the human placenta 
(Redman and Sargent, 2007). This release generates a sub-
stantial  amount  of  placenta-derived  microparticles  in  the 
blood of pregnant women (Taylor et al., 2006).
The binding of shed placental material to FDCs thus 
presented a physiological context for evaluating how FDC-
bound antigen might influence T cell behavior. As might 
be expected, this material remained associated with FDCs 
for at least several weeks after delivery. Surprisingly, how-
ever, the presentation of shed placental OVA to CD8 T cells 
likewise persisted for several weeks into the postpartum period, 
far longer than the lifespan of any individual secondary lym-
phoid organ–resident DC that might have ingested antigen 
during gestation. Further experiments revealed that this ex-
tended phase of antigen presentation was caused by the con-
tinual sampling of FDC-associated OVA depots by progressive 
cohorts of bone marrow–derived DCs. This novel pathway of 
antigen acquisition by DCs could also be detected in virgin 
mice bearing FDCs loaded with classical OVA–anti-OVA   
antigen–antibody immune complexes. In both cases, ensuing 
antigen presentation was highly tolerogenic as it led to the 
deletion of naive OVA-specific CD8 T  cells  even  in  the 
presence of adjuvant-induced inflammation.JEM VOL. 208, January 17, 2011 
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period, we assessed postpartum OT-I proliferative responses 
in Act-mOVA–mated females under conditions in which the 
APCs expressing the H-2Kb MHCI restriction element re-
quired for OVA presentation to OT-I cells would themselves 
only exist in the postpartum period. To this end, we first gen-
erated H-2Kb–deficient mice on a B6CBAF1 background by 
mating B6 background MHCI-deficient H-2Kb/ H-2Db/ 
(Kb/Db/) mice (Pérarnau et al., 1999) with CBA/J mice, 
which bear a H-2k haplotype.  The resultant KbDb B6CBAF1 
mice, which as expected showed no antigen-specific OT-I 
proliferative response after soluble OVA injection (Fig. 2 A), 
were mated to Act-mOVA or control B6 males and then 
from a peripheral tissue reservoir or persisting at low levels 
within the blood itself. Instead, these data together suggested 
that the extended phase of OVA presentation in the postpartum 
period was caused by APCs persistently sampling depots of shed 
placental OVA retained within the LN themselves and raised 
the possibility that these depots were FDC associated.
Persistent presentation of placental OVA is mediated  
by bone marrow–derived APCs that ingest antigen de novo 
in the postpartum period from a radioresistant depot
To substantiate the idea that the APCs presenting OVA ≥3 wk 
after delivery had in fact acquired antigen in the postpartum 
Figure 1.  OVA expression by the conceptus induces OVA accumulation and retention on FDCs and an extended phase of OVA presentation 
in the postpartum period. (A) B6CBAF1 females were mated to either B6 or Act-mOVA males, and secondary lymphoid organs were collected either in 
late gestation (E17.5–18.5; top two rows) or 3 wk after delivery (bottom row). Serial tissue sections were stained with anti-CD35 antibodies (green) to 
identify FDC networks and anti-OVA antibodies to identify OVA deposits (red) and were counterstained with DAPI (blue). Arrows indicate OVA+ immunore-
active material present at 3 wk postpartum. During gestation, OVA FDC networks were occasionally also visible in Act-mOVA–mated mice (arrowhead). 
Data are representative of at least n = 4 mice per group and at least three independent experiments. (B and C) OVA presentation in the subcutaneous LNs 
(scLN) and spleens of 3–4 wk postpartum females. Antigen presentation was assessed by injecting the mice with CFSE-labeled OT-I T cells and then visu-
alizing cell proliferation 44 h later by flow cytometry. B shows, for individual mice, the percentage of OT-I cells having undergone more than one division 
cycle (n = 5–7 mice per group compiled over two independent experiments), whereas C shows representative CFSE dilution plots.138 Follicular dendritic cells in cellular immunity | McCloskey et al.
empirically established to give a reasonable rate of transplant 
acceptance while simultaneously preserving OVA+ FDC net-
works (Fig. S2).
Not surprisingly, OT-I proliferation was undetectable in 
the n = 2 postpartum Act-mOVA–mated KbDb B6CBAF1 
females in which the wild-type bone marrow transfer gave 
only low levels (i.e., 2 and 30%) of donor cell contribution to 
the total CD11c+ MHCII+ DC pool (as assessed in spleen cell 
preparations; unpublished data). Strikingly, however, KbDb 
B6CBAF1 females with high levels of DC chimerism (i.e., 
with  77–99%  of  DCs  being  of  wild-type,  donor  origin;   
Fig. S2) showed robust OT-I proliferation 3 wk after delivery 
in 5 out of n = 6 mice (Fig. 2 B; representative CFSE dilution 
plots are shown in Fig. 2 C). T cell proliferation was antigen 
driven, as it was not evident in B6 control–mated females   
(n = 5), although many of the OT-I cells in both sets of mice 
underwent one round of division, which is consistent with 
their  lymphopenia-induced  homeostatic  expansion. Taken 
with our previous evidence that fetal cells do not directly 
present fetal/placental OVA to maternal T cells (Erlebacher   
et al., 2007), these data formally demonstrated the potential 
for bone marrow–derived APCs generated in the postpartum 
period to acquire antigen from a long-lived antigen depot 
generated during pregnancy. Conversely, the preservation   
of this OVA depot after a radiation-based bone marrow– 
conditioning regimen implied that the depot was associated 
with a radioresistant cell type such as an FDC rather than a 
bone marrow–derived cell type.
Persistent presentation of placental antigen  
in the postpartum period is abrogated by the administration 
of a lymphotoxin  receptor (LTR)–Ig fusion protein
To further implicate FDC-bound OVA as the antigen source 
for persistent presentation, we assessed OT-I proliferative re-
sponses in postpartum Act-mOVA–mated females treated 
with LTR-Ig. This reagent acts as a decoy receptor for the 
FDC survival factor lymphotoxin LT12 and thus induces 
the rapid regression of FDC networks and the dissipation of 
associated immune complexes (Mackay and Browning, 1998). 
Accordingly, Act-mOVA–mated females given a single injec-
tion of LTR-Ig within 1 wk after delivery showed no OVA 
deposits in the subcutaneous LN 3 wk later (i.e., 21–26 d after 
delivery), although CD35+ FDC networks had largely recov-
ered by this point (Fig. S3). Strikingly, LTR-Ig treatment 
also induced a complete loss of postpartum OT-I proliferative 
responses (Fig. 3 A; representative CFSE dilution plots are 
shown in Fig. 3 B). In contrast, OVA+ FDC networks as 
well as OT-I proliferative responses were still apparent in   
Act-mOVA–mated  mice  injected  with  control  polyclonal 
human IgG (hIgG). Disruptions in LT12-induced signal-
ing are known to affect DC homeostasis as well as cells   
such as subcapsular sinus macrophages that help mediate the 
initial transport of immune complexes to FDCs (Kabashima 
et al., 2005; Suzuki et al., 2009). However, postpartum B6-
mated mice showed no detectable impairment in the presen-
tation of soluble OVA injected 3 wk after LTR-Ig treatment   
given 4–5 × 106 wild-type B6CBAF1 bone marrow cells 
within  1  wk  after  delivery  to  generate  H-2Kb–expressing 
APCs. OT-I T cells were then transferred 2 wk after bone 
marrow transfer (i.e., 15–20 d after delivery), and their prolif-
erative response in the subcutaneous LNs was assessed 44 h 
later. Because FDC-associated antigen depots can be obliter-
ated by high doses of irradiation (Phipps et al., 1981), the 
conditioning regimen used in these experiments used a com-
bination of cyclophosphamide administration, NK cell deple-
tion, and sublethal irradiation at a dose (600 cGy) that was 
Figure 2.  Placental OVA is retained by a radioresistant cell type 
and can be acquired by bone marrow–derived APCs generated after 
parturition. (A) Absence of OVA presentation to OT-I cells in KbDb 
B6CBAF1 mice. Virgin KbDb B6CBAF1 and B6CBAF1 mice were either 
left untreated or intravenously injected with 100 µg OVA. After 4 h, the 
mice were given CFSE-labeled OT-I cells. T cell proliferation was then visu-
alized in the subcutaneous LNs 44 h later by flow cytometry. Data are 
from two independent experiments and are representative of n = 2 mice 
in both of the untreated groups, and n = 3 and n = 5 mice in the OVA-
injected B6CBAF1 and KbDb B6CBAF1 groups, respectively. (B and C) OVA 
presentation in Act-mOVA–mated KbDb B6CBAF1 females subjected 
within 1 wk after delivery to a radiation-based bone marrow–conditioning 
regimen and reconstitution with wild-type B6CBAF1 bone marrow. 2 wk 
after transplantation (i.e., 15–20 d after delivery), antigen presentation 
was assessed in the subcutaneous LNs by injecting the mice with CFSE-
labeled OT-I T cells and then visualizing cell proliferation 44 h later by 
flow cytometry. B6-mated KbDb B6CBAF1 females were subjected to 
the same protocol and served as controls. B shows, for individual mice, 
the percentage of OT-I cells having undergone more than one division 
cycle (n = 5–6 mice per group compiled over three independent experi-
ments), whereas C shows representative CFSE dilution plots.JEM VOL. 208, January 17, 2011 
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that both C3 and C4 activation products can 
directly bind CR1/2 (Selander et al., 2006). 
Indeed, mice with a targeted deletion of the 
Cr2 gene (Ahearn et al., 1996), which en-
codes both CR1 and CR2 receptors in mice, showed a dra-
matic, 96% reduction in the number of OVA+ FDC foci per 
splenic cross section (Fig. 4 A).
Importantly, none of these complement system deficien-
cies appreciably reduced the systemic proliferation of OT-I   
T cells adoptively transferred in late gestation, when antigen 
presentation was likely mediated predominantly by DCs that 
had directly acquired antigen from the blood (Fig. 4 B). Al-
though the complement system was thus critical for efficient 
binding of shed placental material to FDCs, it was not in-
volved in antigen shedding per se. Similarly, we observed sys-
temic OT-I proliferation, and thus OVA shedding, in late 
gestation Act-mOVA–mated  females  variously  deficient  in   
B cells (MT mice; Fig. 4 B), perforin (Pfp/ mice), or NK 
cells (Il15/ mice; Fig. S4).
Classical antigen–antibody immune complexes retained  
by FDCs are also persistently sampled by bone  
marrow–derived APCs
To determine whether the sampling of FDC-bound antigen 
by bone marrow–derived APCs was relevant only to placenta-
derived material and/or the postpartum period, we next as-
sessed whether it was also apparent in virgin mice bearing 
classical antigen–antibody immune complexes. As shown in 
Fig. 5 A, B6CBAF1 virgin females showed clear OT-I prolif-
erative responses in the subcutaneous LNs 3 wk after their 
intravenous injection with 100 µg soluble OVA and 250 µg 
rabbit anti-OVA antibodies. This extended phase of pre-
sentation was coincident with the long-term retention of   
(Fig. 3 B, right), indicating that antigen presentation by itself 
was largely intact at the time we transferred OT-I T cells into 
LTR-Ig–treated Act-mOVA–mated females, and we note 
that these latter mice received LTR-Ig when their FDCs 
were already OVA loaded. Thus, LTR-Ig inhibited the per-
sistent postpartum presentation of placental OVA likely be-
cause it specifically disrupted FDC networks and induced 
their loss of bound antigen.
OVA shed from the placenta binds maternal FDCs  
in a complement-dependent fashion
Given the critical role of complement in antigen binding by 
FDCs,  we  next  assessed  placental  OVA  shedding  and  the 
binding of shed OVA to FDCs in late gestation Act-mOVA–
mated females deficient in various components of the com-
plement system. As shown in Fig. 4 A, the number of OVA+ 
FDC foci visible per splenic cross section was reduced 70% 
in C1qa/ mice (Botto et al., 1998) deficient in the comple-
ment component C1q, which is a key initiator of the classical 
pathway, as well as in mice deficient in C4 (Wessels et al., 
1995), which is a component of both classical and mannose-
binding lectin pathways. The number of OVA+ FDC foci per 
splenic cross section was also reduced 50% in mice deficient 
in C3 (Wessels et al., 1995), which is the central component 
of the classical, alternative, and mannose-binding lectin path-
ways, although the reduction did not reach a P < 0.05 level of 
statistical significance. Most likely, the moderate effect of each 
individual complement component deficiency reflected the 
existence of bypass complement pathways and the observation 
Figure 3.  The extended phase of postpartum 
OVA presentation is abrogated in mice treated 
with LTR-Ig. (A and B) Females were mated to 
either B6 or Act-mOVA males and within 1 wk after 
delivery were injected with either control hIgG or 
LTR-Ig. 21 d later (i.e., 21–26 d after delivery), anti-
gen presentation was assessed in the subcutaneous 
LNs by injecting the mice with CFSE-labeled OT-I  
T cells and then visualizing cell proliferation 44 h 
later by flow cytometry. A shows, for individual mice, 
the percentage of OT-I cells having undergone more 
than one division cycle (n = 3 and n = 8–9 mice for 
B6-mated and Act-mOVA–mated groups, respectively, 
compiled over three independent experiments), 
whereas B shows representative CFSE dilution plots. 
Some postpartum B6-mated females shown in B 
were also intravenously injected with 100 µg OVA 
immediately before receiving OT-I cells; the percent-
age of OT-I cells having undergone more than one 
division cycle in these mice was not significantly 
different between the hIgG- and LTR-Ig–treated 
subgroups (73.4 ± 5.6% vs. 62.5 ± 13.4%, respec-
tively; mean ± SD; n = 4 mice per group compiled 
over two independent experiments; P = 0.19).140 Follicular dendritic cells in cellular immunity | McCloskey et al.
B6 mice showed systemic OT-I proliferation and OVA accu-
mulation on FDCs (Fig. 4), antigen did not persist on LN 
FDC networks in these mice for much longer than 1 wk after 
delivery, nor did these mice show convincing OT-I prolifera-
tion more than 1–2 wk after delivery (unpublished data), 
which is in line with previous data (Moldenhauer et al., 2009). 
Similar data were obtained with Act-mOVA–mated BALB/c 
females and CD4+ DO11.10 TCR transgenic anti-OVA T cells, 
as well as with B6 virgins injected with OVA and anti-OVA 
antibodies (unpublished data). These results are likely explained 
by the well-known strain-specific differences in complement 
physiology (Falus et al. [1987] and references therein), which 
may affect antigen-loading capacities or rates of antigen turn-
over on the FDC cell surface. Indeed, approximately two times 
more OVA+ FDC foci per LN cross section were initially 
formed by equivalent amounts of OVA–anti-OVA immune 
complexes in B6CBAF1 and CBA/J mice, as compared with 
B6 and BALB/c mice, and these immune complexes were 
still clearly visible 3 wk later in B6CBAF1 and CBA/J mice 
but  not  in  B6  and  BALB/c  mice  (Fig.  S6). These  strain- 
specific differences meant that Cr2/ mice, which were on a 
B6 background, could be used for demonstrating the comple-
ment dependence of antigen loading onto FDCs (e.g., Fig. 4) 
OVA–anti-OVA immune complexes on LN FDCs (Fig. 5 B) 
and contrasted with the virtual total loss of OT-I proliferative 
responses in B6CBAF1 virgin females 7 d after their intrave-
nous injection with 100 µg soluble OVA alone (Fig. S1 A).   
As with the response to placental OVA, OT-I T cells showed 
an extended phase of proliferation in the LNs but not the 
spleen (Fig. S5), in correlation with the rapid disappearance of 
splenic OVA+ FDC foci (not depicted). As shown in Fig. 5 C, 
the extended phase of OVA presentation could also be seen   
in KbDb B6CBAF1 mice bearing OVA–anti-OVA immune 
complexes that were sublethally irradiated and reconstituted 
with wild-type B6CBAF1 bone marrow as above (see section 
describing Fig. 2) and, conversely, was reduced in B6CBAF1 
mice treated with LTR-Ig (Fig. 5 D). As expected (Wu et al., 
2000), the loading of OVA–anti-OVA immune complexes onto 
FDCs was complement dependent, as splenic OVA+ FDC net-
works were apparent in control B6 but not Cr2/ mice 2 d 
after antigen and antibody injection (unpublished data).
Together, these data indicate that the persistent sampling 
of FDC-bound antigen by bone marrow–derived APCs is a 
general phenomenon. However, it is notable that our ability 
to visualize the pathway was confined to mice on a B6CBAF1 
background. Thus, although late gestation Act-mOVA–mated 
Figure 4.  Complement and antibody involvement in placental OVA shedding and FDC accumulation. (A) OVA accumulation on FDC networks in 
complement- and CR1/2-deficient mice. After mating to Act-mOVA males, spleens were collected on E17.5–19.5 from control B6 females (n = 16) or fe-
males deficient in various components of the complement system (C1qa/ [n = 9], C4/ [n = 8], C3/ [n = 8], or Cr2/ [n = 6] mice compiled over at 
least three independent experiments per group), and tissue sections were stained with anti-OVA antibodies. The mean number of OVA+ FDC networks per 
splenic cross section is displayed ± SEM. (B) Systemic OVA presentation in complement-, CR1/2-, and B cell–deficient (µMT) mice. Knockout or control B6 
females were mated to B6 or Act-mOVA males, and antigen presentation was assessed in the spleen by injecting the mice with CFSE-labeled OT-I T cells 
on E14.5–19.5. Cell proliferation was then visualized 42–44 h later by flow cytometry. Data are representative of n = 2–9 Act-mOVA–mated mice per 
group, each from a least two independent experiments.JEM VOL. 208, January 17, 2011 
Article
141
but not B6 control–mated females. In contrast, no antigen-
specific response was seen when OT-I cells were co-cultured 
with Langerhans cells, plasmacytoid DCs, or B cells isolated 
from postpartum Act-mOVA females, and only a low and in-
consistent level of antigen-driven proliferation was seen in 
co-cultures with non–Langerhans cell CD11cint MHCIIhi mi-
gratory DCs (Fig. 6 A).
Conversely, we assessed whether DCs were required for 
the extended phase of antigen presentation. These experi-
ments were performed in the context of FDCs loaded with 
classical antigen–antibody immune complexes and took ad-
vantage of CD11c–diptheria toxin (DT) receptor (DTR) 
transgenic mice, which through their CD11c promoter– 
directed expression of the DTR render DCs susceptible to 
DT-induced  ablation  (Jung  et  al.,  2002).  Specifically,  we 
loaded  FDCs  in  KbDb  B6CBAF1  females  with  100  µg 
but not for evaluating the overall complement dependence of 
persistent antigen presentation.
LN-resident DCs are the primary cell type that acquires 
FDC-bound antigen for presentation to CD8 T cells
Currently, DCs are the only cell type thought to have the ca-
pacity to efficiently process exogenous antigens for cross- 
presentation on MHCI molecules. To confirm that DCs were 
mediating the presentation of FDC-bound antigen, and to 
identify the relevant DC subset or subsets, we performed   
ex vivo antigen presentation assays using various APC popu-
lations sorted from the subcutaneous LNs of postpartum 
mice. As shown in Fig. 6 A, LN-resident DCs (i.e., the CD11chi 
MHCIIint population; see Fig. S7 for our sorting scheme) 
induced  a  clear  proliferative  response  in  co-cultured  OT-I   
T cells when the DCs were isolated from Act-mOVA–mated 
Figure 5.  Acquisition and presentation of FDC-retained antigen–antibody immune complexes. Immune complexes were formed in vivo by intra-
venously injecting B6CBAF1 mice with 250 µg rabbit anti-OVA followed by 100 µg OVA. Subcutaneous LN cells were analyzed by flow cytometry 44 h 
after OT-I injection. (A) Persistent OVA presentation. Mice were given OT-I T cells 3 wk after immune complex formation. Data are representative of  
n = 4–5 mice per group (two independent experiments). As expected, the injection of anti-OVA antibodies alone did not induce OT-I proliferation (not 
depicted). (B) OVA persistence on FDC networks 3 wk after immune complex formation. Serial LN tissue sections were stained with anti-CD35 (green) and 
anti-OVA (red) antibodies and counterstained with DAPI. Data are representative of n = 5–8 mice per group and at least three independent experiments. 
(C) Persistent sampling of antigen–antibody immune complex depots by bone marrow–derived APCs. KbDb B6CBAF1 mice were reconstituted wild-type 
B6CBAF1 bone marrow 2 d after immune complex formation and then given OT-I T cells 14 d after transplantation. Data are representative of n = 5–6 
mice per group (two independent experiments). The mean percentage of cells undergoing more than one division cycle in untreated versus immune  
complex–bearing mice was 27.3 ± 3.3% versus 43.0 ± 4.7% (mean ± SEM; P = 0.02). (D) Abrogation of persistent OT-I proliferative responses in mice 
treated with LTR-Ig. Mice were injected with LTR-Ig or control hIgG 2 d before immune complex formation and then given OT-I T cells 14 d later. Data 
are from n = 6 mice per group compiled over two independent experiments.142 Follicular dendritic cells in cellular immunity | McCloskey et al.
approach involved assessing the 5-d expansion of OT-I T cells 
transferred into postpartum Act-mOVA–mated females 14–17 d 
after delivery, when it was likely that virtually all of the pre-
sented OVA would have been acquired from FDC-associated 
depots. To provide positive controls for T cell deletional toler-
ance and T cell priming, we injected virgin females intrave-
nously on the day of OT-I transfer with endotoxin-free, 
soluble OVA, with or without the adjuvant combination of 
agonistic anti-CD40 antibodies and the TLR3 agonist poly-
inosinic:polycytidylic acid (poly(I:C)). These adjuvants would 
be expected to convert the poor CD8 T cell response induced 
by antigen alone to strong T cell priming, even in the absence 
of CD4 T cell helper function (Ahonen et al., 2004). The dose 
of injected OVA (10 µg) was chosen because it was the lowest 
known to give good OT-I proliferative responses (Li et al., 
2001); the doses of anti-CD40 antibodies and poly(I:C) (30 µg 
and 15 µg, respectively) were based on an empirical estimation 
(unpublished data) of the minimum required to induce good con-
version of T cell deletion to T cell priming.
As expected, control virgin females injected with OVA 
alone showed OT-I proliferation without a significant nu-
merical expansion of the cells (Fig. 7 A, compare CFSE dilu-
tion plots with graph), suggesting that proliferation was matched 
OVA–250 µg anti-OVA immune complexes and then 2 d later 
performed the sublethal irradiation-based protocol described 
above (see section describing Fig. 2) to transplant them with 
bone marrow from CD11c-DTR mice. 12 d after transplanta-
tion, we started giving half the mice daily intravenous injections 
of DT and then transferred OT-I T cells 14 d after transplant to 
detect OVA presentation. As compared with non-DT–treated 
mice, DT-treated mice showed significantly reduced OT-I pro-
liferation (Fig. 6 B), with the remaining proliferation in some of 
these mice attributable to the inability of intravenous DT injec-
tion to completely deplete all LN-resident DCs (as opposed to 
splenic DCs; not depicted). Although DT treatment of CD11c-
DTR mice is known to affect cell types other than DCs (e.g., 
Probst et al., 2005), these data, when considered in combination 
with the results of our ex vivo co-culture experiments, provide 
strong evidence that LN-resident DCs are the primary, if not 
exclusive, cell type acquiring antigen from FDC depots for sub-
sequent presentation to CD8 T cells.
Tolerogenic T cell responses to the presentation of FDC-
retained OVA, even in the presence of exogenous adjuvants
Lastly, we asked whether the presentation of antigen acquired 
from FDC depots was tolerogenic or immunogenic. Our first 
Figure 6.  FDC-associated antigens are presented by LN-resident DCs. (A) Ex vivo co-culture. B6CBAF1 females were mated to either B6 or  
Act-mOVA males, and 10–21 d after delivery, subcutaneous LNs were collected and respectively pooled for each group of mice. Sorted populations were 
then co-cultured with CFSE-labeled OT-I cells, and cell proliferation was assessed 90 h later. Representative data are from one of three independent ex-
periments and show results for an APC/T cell ratio of 8 × 103:5 × 104. (B) Dependence of FDC-associated antigen presentation on CD11c+ APCs. KbDb 
B6CBAF1 virgins were reconstituted with CD11c-DTR bone marrow 2 d after immune complex formation and then given CFSE-labeled OT-I T cells 2 wk 
later to assess antigen presentation. Cell proliferation in the subcutaneous LNs was visualized 44 h later by flow cytometry. The indicated animals began 
receiving daily intravenous injections of 100 ng DT starting 2 d before OT-I transfer. Given the high degree of antigen-nonspecific proliferation seen after 
bone marrow transplantation (see Figs. 2 C and 5 C), we analyzed proliferation as the percentage of OT-I cells having undergone more than two, rather 
than one, division cycles (n = 6 animals per group compiled over two independent experiments).JEM VOL. 208, January 17, 2011 
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injection of anti-CD40 antibodies plus poly(I:C) into Act-
mOVA–mated females did not convert this response to T cell 
priming, as we failed to detect any consistent numeric expansion 
of the OT-I cells despite them undergoing more division cycles. 
Indeed,  the  fold  expansion  over  nonadjuvant-treated  Act- 
mOVA–mated mice was at maximum only approximately 
eightfold, and the mean fold expansion was only approxi-
mately threefold. Interestingly, several of these mice showed 
decreased T cell recovery compared with untreated controls.
Together, these results suggested that the presentation of 
FDC-bound placental OVA was not only inherently tolerogenic 
but could even induce T cell deletion 
in  the  presence  of  exogenous  adju-
vants. To substantiate and extend these 
findings, we used our alternative model 
of  antigen  acquisition  and  presenta-
tion  based  on  the  loading  of  FDCs 
with  defined  quantities  of  classical   
antigen–antibody immune complexes 
(i.e., 100 µg OVA plus 250 µg anti-
OVA antibodies injected into virgin 
with concurrent cell deletion. In contrast, adjuvant coinjec-
tion induced extensive OT-I proliferation and a mean 55-fold 
expansion of the cells (Fig. 7 A) and their expression of IFN- 
(not depicted). A similar pattern was observed using post-
partum B6-mated females, which demonstrated that the path-
ways mediating T cell priming remained generally intact in the 
postpartum period (Fig. 7 A). Postpartum Act-mOVA–mated 
female mice also showed OT-I proliferation without significant 
T cell accumulation, just like control mice injected with OVA 
in the absence of adjuvants (Fig. 7 A). However, in direct contrast 
to the response of virgin and B6-mated control mice, the   
Figure 7.  Tolerogenic T cell responses to 
FDC-associated antigen. Mice were injected 
with CD45.1-marked, CFSE-labeled OT-I  
T cells, and cell proliferation was assessed in 
the subcutaneous LNs 5 d later. For each ex-
periment, the fold OT-I expansion for each 
mouse was calculated by normalizing the  
OT-I/total CD8+ T cell ratio to the mean for 
this ratio in the virgin, untreated group. The 
numeric fold differences shown were calcu-
lated from the mean fold expansion for each 
group (bars). The plots showing CFSE dilution 
versus expression of the activation marker 
CD62L come from single experiments.  
(A) Responses to shed placental OVA. B6- and 
Act-mOVA–mated females were given OT-I 
cells 14–17 d after delivery; virgins were pro-
cessed in parallel. Some mice were injected as 
indicated with OVA and/or anti-CD40 anti-
bodies (-CD40) plus poly(I:C) 4–6 h before 
OT-I transfer. Data are from n = 5–11 mice per 
group (five independent experiments). The 
Act-mOVA–mated groups only include mice 
that showed OT-I proliferation and thus had 
FDC-retained OVA available for presentation. 
(B) Responses to OVA–anti-OVA immune 
complexes in virgin mice. For groups 1–8, 
mice were loaded with or without immune 
complexes and then given OT-I cells 16 d later. 
Some mice were injected as indicated with  
-CD40 antibodies plus poly(I:C) 4–6 h before 
OT-I transfer and/or with -CD25 antibodies 
12 d after immune complex formation. 
Groups 9 and 10 were given immune com-
plexes 4–6 h immediately before OT-I transfer. 
Data are from n = 5–9 animals per group 
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remains undefined. Previously, we showed that OVA accumu-
lation on FDCs during pregnancy did not involve the simple 
proteolytic release of OVA from the trophoblast cell surface 
(Erlebacher et al., 2007). Therefore, it is likely that the pro-
tein encoded by the Act-mOVA transgene continues to be   
membrane-associated upon its release from the placenta and that 
it is some component of this membranous material that medi-
ates  complement  deposition  and  FDC  binding.  Moreover, 
our demonstration here that shedding was independent of the 
complement system, antibodies, or NK cells suggests that the 
process was intrinsic to placental trophoblasts. Analogously, 
the human placenta is known to release large amounts of sub-
cellular material, including >100-nm-diameter microparticles 
occasionally containing the nuclear remains of apoptotic syn-
cytiotrophoblasts, as well as the 40–100-nm-diameter multi-
vesicular body–derived particles known as exosomes (Redman 
and Sargent, 2007). Both apoptotic material and exosomes 
can be opsonized by complement (Bard et al., 2004; Papp et al., 
2008; Paidassi et al., 2009), which in the case of exosomes 
likely mediates FDC binding (Denzer et al., 2000; Qazi et al., 
2009). Because the accumulation of placental OVA on mater-
nal FDCs was apparent as early as embryonic day (E) 11.5, 
before any substantial T cell response to the placenta (Erlebacher 
et al., 2007), it is unlikely that the FDC binding of placental 
OVA requires an induced maternal antibody response to OVA 
or to any other T-dependent placental antigen. In contrast, it 
remains possible that natural antibodies with placental reac-
tivity or antiplacental antibodies arising in late gestation con-
tribute to FDC binding.
Although our results provide firm evidence that DCs per-
sistently sample FDC-retained antigen, the exact mechanism 
of antigen acquisition is currently unclear. Provocatively, the 
presence of scattered DCs within B cell follicles (Berney et al., 
1999; Yu et al., 2002; Lindquist et al., 2004) suggests a short- 
range process that allows DCs to sample the follicular anti-
genic environment before migrating to the T cell zones. 
Interestingly, cognate B cells have recently been shown to ac-
quire FDC-bound immune complexes via a pathway that in-
volves direct cell–cell contact, surface Ig, and capture of CD157, 
an FDC cell surface marker (Suzuki et al., 2009). Although an 
analogous pathway might also be available to DCs if mediated 
by non-Ig receptors, we have found that the surface levels of 
CD157 on LN DCs, which were rather appreciable in some 
DC  subsets,  were  not  significantly  altered  after  LTR-Ig 
treatment (unpublished data). This suggests that DC-associated 
CD157  is  expressed  cell-intrinsically  rather  than  acquired 
from FDCs. Furthermore, direct B cell capture of FDC-retained 
antigen has been observed as late as 9 d after immune com-
plex formation, when the complexes are mainly condensed 
into large, 0.3-µm-diameter iccosomes (Suzuki et al., 2009). 
In contrast, immune complexes retained by FDCs for >1 wk 
become diffusely localized over FDC dendrites and appear to 
be ingested preferentially by tingible body macrophages   
(Szakal et al., 1988). It is unknown whether this latter process 
is more relevant to DCs and whether it involves direct cell–
cell contact or the release of antigen from the FDC surface   
mice). As shown in Fig. 7 B, this model was also associated 
with OT-I T cell proliferation without a significant degree of 
cell expansion when the cells were transferred 16 d after im-
mune complex formation (compare group 1 with group 2). 
Furthermore, injection of anti-CD40 antibodies plus poly(I:C) 
at the time of T cell transfer not only failed to induce T cell 
priming but instead induced a dramatic loss of cells (group 4). 
This extreme phenotype was antigen dependent because OT-I 
cell numbers remained relatively high in antigen-free mice 
that were adjuvant injected at the time of T cell transfer, even 
though the cells underwent some level of bystander prolifera-
tion (group 3). The overall pattern of response was unchanged 
when the mice were given anti-CD25 antibodies to deplete 
natural T reg cells and any T reg cell potentially induced by 
OVA exposure during the weeks before OT-I adoptive trans-
fer (groups 5–8).
Importantly, OT-I cells transferred with adjuvant on the 
same day of immune complex formation underwent robust 
expansion (29-fold compared with that induced by immune 
complexes alone; >100-fold compared with untreated controls; 
Fig. 7 B, groups 9 and 10). In this latter situation, some im-
mune complexes were presumably taken up directly by DCs 
without first being bound into FDC-associated depots. Lastly, 
mice given adjuvants at the time of immune complex forma-
tion still showed OT-I deletion when the cells were given 16 d 
later (Fig. S8). Together, these data revealed the acquisition 
and presentation of FDC-bound antigen by DCs to be a re-
markably tolerogenic pathway for CD8 T cells that is indepen-
dent of the physical form of the loaded antigen (membranous 
placental  material  versus  antigen–antibody  immune  com-
plexes), T reg cells, and the level of inflammation at the time 
of initial antigen loading or ultimate TCR engagement.
DISCUSSION
Because of the physical separation between B cell follicles and 
the T cell zones, the function of FDCs has thought to be 
confined exclusively to the realm of humoral immunity. Con-
trary to this view, we present evidence in this study that   
FDC-associated antigen depots are persistently sampled by 
LN-resident DCs to regulate the T cell immune response. 
This evidence is founded on the observation that the retention 
of antigen by LN FDCs correlated with extended phases of 
antigen presentation to LN CD8 T cells. Functionally, we 
showed that these extended phases involved continual antigen 
acquisition by bone marrow–derived APCs and a radioresistant 
antigen depot. We then showed that the antigen depots were   
indeed FDC associated and that the APCs were LN-resident 
DCs. As discussed in the following paragraphs, the pathway 
links several critical, but poorly understood factors that regulate 
T cell immune responses, including antigen persistence, com-
plement activation, and the clearance of apoptotic material.
The acquisition and presentation of FDC-bound antigen 
appears to be a general process because it applies to at least 
both classical antigen–antibody immune complexes as well as 
the immune complexes formed from shed placental material. 
At present, the exact composition of these latter complexes JEM VOL. 208, January 17, 2011 
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recently been attributed to the sampling of residual antigen 
depots within the lungs by pulmonary DCs, before their mi-
gration to the mediastinal LN (Kim et al., 2010). These depots 
are radioresistant and have been suggested to be associated 
with FDCs present within infection-induced tertiary lymphoid 
structures because LTR-Ig treatment diminished the num-
ber of CD4 T cells proliferating in response to residual influ-
enza antigen. However, antigen was not directly shown to be 
associated with lung FDCs, and LTR-Ig treatment also di-
minished naive anti-influenza CD4 T cell numbers within the 
mediastinal LN, leading to a relatively unchanged CFSE dilu-
tion profile (Kim et al., 2010). This response starkly contrasts 
with the complete abrogation of antigen presentation we ob-
served in our system. Thus, the role of FDCs in the presenta-
tion of residual influenza virus antigen remains to be completely 
established. It is also unclear how a single pathway would ex-
plain the observation that residual influenza antigen presenta-
tion can promote T cell memory in the CD4 but not CD8 
compartment (Jelley-Gibbs et al., 2005, 2007). Nonetheless, 
these results together with ours suggest that the sampling of 
radioresistant antigen depots may have different effects on the 
quality of the T cell response depending on the type of depot, 
the subset of sampling DC, and the type of T cell.
We are also struck by the potential relevance of the anti-
gen sampling pathway described in this study to the patho-
genesis of systemic lupus erythematosus (SLE), an autoimmune 
disease characterized by the production of antibodies pre-
dominantly toward the nuclear autoantigens concentrated 
within the membrane-associated microparticles (i.e., blebs) 
produced by apoptotic cells (Casciola-Rosen et al., 1994; for 
review  see  Manderson  et  al.,  2004).  Specifically,  our  data 
would suggest that any defect in the ability of FDCs to retain 
immune complexes, or for DCs to acquire these immune 
complexes, might limit the peripheral deletion of T cells reac-
tive toward the autoantigens associated with complement-
opsonized apoptotic microparticles. The ensuing increase in 
the number of naive SLE-relevant autoreactive T cells would 
increase the risk of their activation, which would in turn set 
the stage for a loss of B cell tolerance. This hypothesis applies 
to the preclinical stages of the disease and assumes that the 
constitutive, DC-mediated presentation of apoptotic material 
acquired from FDCs indeed constitutes a physiologically sig-
nificant  pathway  for  tolerizing  SLE-relevant  autoreactive   
T cells, a postulation which needs experimental verification. 
However, the hypothesis is consistent both with the SLE pre-
disposition seen in patients with genetic deficiencies in up-
stream components of the classical complement pathway (i.e., 
C1q, C2, and C4; for review see Manderson et al., 2004) and 
the  association  between  SLE  susceptibility  and  polymor-
phisms in ITGAM, which encodes the  chain (i.e., CD11b 
component) of CR3 (Moser et al., 2009), as well as with the 
finding  that  apoptotic  material  is  often  tolerogenic  under 
physiological conditions (Paidassi et al., 2009). Moreover, the 
hypothesis is consistent with the observation that SLE, while 
associated with the impaired clearance of apoptotic material 
(for review see Manderson et al., 2004), tends to be better 
and its transient cell-free diffusion. Such diffusion might also 
allow released antigen to reach the T cell zones. Further work 
will also be required to elucidate the receptors that mediate 
antigen uptake by DCs, as they might include the CD11b/
CD18 (CR3) and CD11c/CD18 (CR4) complement recep-
tors (which would be relevant to the immune complexes 
formed from both antibodies as well as membranous mate-
rial), Fc receptors (which would be relevant only to antibody-
containing immune complexes), the scavenger receptor CD36 
or the integrins v3 and v5 (which might be relevant 
only to cases of membrane-associated material), or more anti-
gen-specific receptors (such as the mannose receptor in the 
case of OVA).
The engagement of CR3 during the acquisition of FDC-
bound OVA is a particularly attractive possibility because it 
might help explain why the presentation of acquired antigen 
was so tolerogenic. Recent work has demonstrated that DC 
activation is suppressed upon ligation of CR3 (and to a less 
well-established extent CR4), even if the cells are also ex-
posed to LPS or CD40 ligand (Verbovetski et al., 2002;   
Morelli et al., 2003; Sohn et al., 2003; Skoberne et al., 2006; 
Behrens et al., 2007). This is analogous to our data showing 
that the presentation of FDC-associated OVA still induced 
OT-I deletion when the mice were given anti-CD40 anti-
bodies and poly(I:C) at the time of T cell transfer. Paradoxi-
cally, these adjuvants even enhanced T cell deletion. However, 
it is unlikely that ligation of DC CR3 (or CR4) was alone 
responsible for tolerance induction to FDC-bound OVA be-
cause the concurrent injection of adjuvant, immune com-
plexes and OT-I cells induced strong T cell priming, as 
expected. This result conversely indicates that tolerance was 
also not being induced solely by a component of the immune 
complexes themselves. Given that tolerance also showed no 
requirement for T reg cells, our data instead suggest that DCs 
acquiring antigen from FDC-associated depots require a fac-
tor produced specifically with the follicle if not by the FDC 
itself to assume a tolerogenic phenotype. It is also possible that 
the DCs acquiring antigen from FDC-associated depots are 
intrinsically specialized for tolerance induction.
The tolerogenic sampling of FDC-bound antigen by   
LN-resident DCs might have implications for any situation in-
volving antigen presentation and complement activation. For 
example, the pathway might help explain the systemic sup-
pression of antifetal/placental T cell responses observed during 
pregnancy (Erlebacher et al., 2007), as well as situations in 
which exogenous antigen–antibody immune complexes are 
tolerogenic (Mosconi et al. [2010] and references therein). 
Moreover, the pathway might contribute to the range of CD8 
T cell dysfunction (which includes T cell deletion) associated 
with certain chronic viral infections (Shin and Wherry, 2007). 
This latter possibility is consistent with the expectation that 
antivirus antibodies arising during infection would generate 
FDC-associated viral antigen depots, as well as with our ob-
servation that T cells are deleted even under conditions of   
inflammation. Interestingly, the persistent T cell response to 
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for CD62L expression (MEL-14). Donor DCs were identified after bone 
marrow transplantation as being CD45.1+ CD19 (6D5) CD11c+ (HL3) 
MHCII+ (M5/114.15.2) and were subtyped using antibodies toward CD8 
and CD11b (M1/70). Antibodies were obtained from BD or BioLegend.
Hysterectomies.  Mice  were  anesthetized  with  a  ketamine/xylazine/
acepromazine cocktail, and a lower abdominal transverse incision was made 
to expose the uterus. The uterus was removed after ligating the cervical base 
and the cranial end of each uterine horn with Coated Vicryl 5-0 sutures 
(Ethicon). The abdominal wall was sutured closed, and the skin incision was 
closed with wound clips. Sham operations duplicated this protocol excluding 
ligation and removal of the uterus.
Bone marrow transplantation. Mice were irradiated with 600 cGy   
cesium-137-sourced -radiation (Gammacell 40; MDS Nordion) and then 
immediately injected intravenously with 4–5 × 106 congenically marked 
CD45.1 B6CBAF1 or CD11c-DTR bone marrow cells. The mice were 
concomitantly injected intraperitoneally with 250 µg anti-NK1.1 NK cell–
depleting antibodies (PK136; Bio X Cell) and 2 d later with 200 mg/kg   
cyclophosphamide  (Sigma-Aldrich),  as  adapted  from  previous  protocols 
(Sharabi et al., 1990; Tomita et al., 2000). The mice were given water supple-
mented with 1% Sulfatrim antibiotics for the remainder of the experiment 
and were injected with 106 CFSE-labeled OT-I T cells 2 wk after transplanta-
tion. OT-I cells were not rejected in mice with high levels of chimerism, as 
expected. For the control experiment involving untransplanted mice (Fig. 2 A),   
it was necessary to give the mice 250 µg anti-NK1.1 antibodies at the time 
of T cell transfer, in addition to an increased number of transferred cells (3 × 106), 
so that appreciable numbers of OT-I cells would remain for analysis 2 d later.
Other reagents, immune complex generation, LTR-Ig–mediated 
FDC depletion, DT-mediated DC depletion, and T reg cell depletion. 
OVA (grade VI; Sigma-Aldrich) and rabbit anti-OVA (Fitzgerald Industries 
International) were applied to Detoxi-Gel columns (Thermo Fisher Scien-
tific) to reduce endotoxin levels to <0.012 endotoxin unit per mg, as determined 
by the Limulus Amebocyte Lysate test (BioWhittaker). All OVA–anti-OVA im-
mune complexes were formed in vivo via intravenous injection of 250 µg 
anti-OVA antibodies immediately followed by intravenous injection of 100 µg 
OVA. Anti-CD40 antibodies were obtained from Bio X Cell, and poly(I:C) 
was obtained from GE Healthcare. The mouse LTR–human Ig (LTR-Ig) 
fusion reagent was the gift of J. Browning (Biogen Idec, Weston, MA), and 
control polyclonal human IgG was obtained from MP Biomedicals. Both of 
these reagents were intravenously injected at 100 µg. 100 ng DT (EMD) was 
given daily for 4 d by intravenous injection. T reg cells were depleted in vivo 
by intravenous injection of 500 µg anti-CD25 antibodies (PC61; Bio X Cell) 
4 d before OT-I transfer. Depletion was confirmed at sacrifice by flow cytom-
etry of CD4+ (clone RM4-5) CD25+ (clone 7D4) cells.
DC sorting and ex vivo co-culture with T cells. LN cell suspensions 
were prepared by enzymatic digestion as previously described (Erlebacher   
et al., 2007), pretreated with the FcR-blocking mAb 2.4G2, and then sepa-
rated  into  B  cell–enriched  versus  B  cell–depleted  fractions  by  magnetic 
bead–based negative selection (CD19) on LD columns (Miltenyi Biotec). 
The B cell–depleted fraction was stained with antibodies to MHCII (clone 
M5/114.15.2), CD103 (2E7), CD326 (G8.8), and CD11c (HL3) to identify 
DC subsets (Henri et al., 2010), whereas the B cell–enriched fraction was 
stained with antibodies to MHCII and CD19 (6D5) to identify B cells. Sort-
ing was performed on a MoFlo cell sorter (Dako). Serial twofold dilutions of 
0.1–32 × 104 DCs were co-cultured with 5 × 104 CFSE-labeled CD45.1 
OT-I cells in V-bottom 96-well dishes as described previously (Belz, 2010). 
After 90 h, the T cells were visualized by flow cytometry as the CD8+  V2+ 
CD45.1+ population.
Statistical analysis. The percentage of OT-I cells engaged in antigen-driven 
proliferation in different postpartum Act-mOVA mice did not fall into a 
normal distribution, as some mice (approximately one out of five) did not 
modeled in gene-targeted mice when the induced deficien-
cies impair both apoptotic cell engulfment as well as FDC 
function (e.g., as with deficiencies in C1q, C4, Mfge8 [milk 
fat globule epidermal growth factor 8], or lymphotoxin sig-
naling), rather than apoptotic cell engulfment alone (e.g., as 
with deficiencies in CD14, CD36, 3 integrin, or 5 integ-
rin; Taylor  et  al.,  2000;  Ravichandran  and  Lorenz,  2007; 
Kranich et al., 2008).
MATERIALS AND METHODS
Mice. B6CBAF1/J (B6CBAF1), B6, CBA/J, and BALB/c were purchased 
from The Jackson Laboratory. Act-mOVA (also called CAG-OVA), C3/, 
and MT mice, all on B6 backgrounds, were purchased from The Jackson 
Laboratory.  OT-I  Rag1/,  MHCI-deficient  H-2Kb/  H-2Db/  (Kb/ 
Db/),  B6.SJL-Ptprca/BoyAiTac  (B6  CD45.1),  Pfp/,  and  Il15/  mice 
were all on B6 backgrounds and were purchased from Taconic. OT-I Rag1/ 
and Kb/Db/ males were mated to CBA/J females to generate B6CBAF1 
OT-I and KbDb B6CBAF1 mice, respectively. OT-I Rag1/ mice were 
also crossed to B6 CD45.1 mice, and their offspring then to CBA/J mice, to 
generate OT-I CD45.1 B6CBAF1 mice. B6 CD45.1 and CBA/J mice were 
crossed to generate the CD45.1 B6CBAF1 mice used as bone marrow do-
nors. C1qa/ (Botto et al., 1998), C4/ (Wessels et al., 1995), Cr2/ 
(Ahearn et al., 1996), and CD11c-DTR (Jung et al., 2002) mice, all on B6 
backgrounds, have been previously described. Mice were maintained in a 
specific pathogen-free facility, and all experiments were approved by the 
New York University School of Medicine Institutional Animal Care and Use 
Committee. All mating experiments used virgin females; noon of the day of 
the appearance of a copulation plug was counted as E0.5. Genotyping of   
Act-mOVA pups was performed as previously described (Erlebacher et al., 
2007); only those Act-mOVA–mated mice that generated a litter containing 
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amplification (PerkinElmer). The sections were then incubated with Alexa 
Fluor 594– or Alexa Fluor 488–conjugated streptavidin (Invitrogen) and 
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show a detectable response despite having Act-mOVA+ pups. Thus, a two-
tailed Mann-Whitney test was used for all comparisons involving OT-I pro-
liferation in Act-mOVA–mated females, including the fold expansion data 
shown in Fig. 7 A. For consistency, a two-tailed Mann-Whitney test was also 
used to analyze the data in Fig. 7 B. All other comparisons were performed 
using a two-tailed Student’s t test. P < 0.05 was taken as the cutoff for statisti-
cal significance.
Online supplemental material. Fig. S1 shows the kinetics of OVA pre-
sentation after the intravenous injection of soluble protein into virgin and 
B6-mated postpartum mice and the maintenance of persistent of OVA pre-
sentation and FDC-bound OVA depots in Act-mOVA–mated mice subjected to 
hysterectomy in the immediate postpartum period. Fig. S2 demonstrates OVA 
retention on maternal FDCs and the appearance of donor-derived DCs ac-
cording to application of the bone marrow transfer protocol used to generate the 
data shown in Fig. 2. Fig. S3 shows recovery of FDC networks but loss of their 
antigen depots 3 wk after a single injection of LTR-Ig. Fig. S4 shows that 
placental antigens are shed and presented to T cells in mice deficient in perforin 
and NK cells. Fig. S5 shows that the formation of OVA–anti-OVA immune 
complexes leads to an extended phase of OVA presentation in the subcutane-
ous LN but not the spleen. Fig. S6 illustrates differential loading and retention 
of OVA on LN FDCs in various mouse strains after the formation of OVA–
anti-OVA immune complexes. Fig. S7 illustrates the gating scheme used for 
the sorting experiment of Fig. 6 A. Fig. S8 demonstrates that OT-I T cells do 
not expand when transferred 3 wk after OVA–anti-OVA immune complexes 
were formed in the presence of adjuvants. Online supplemental material is 
available at http://www.jem.org/cgi/content/full/jem.20100354/DC1.
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